Journal of Bone Research
Open Access

Bone Mineralization and Glucose Metabolism: Its Relation and Impacts

Gerhard Carl Hildebrandt^{* *}Correspondence: Gerhard Carl Hildebrandt, Department of Hematology, Markey Cancer Center, University of Kentucky, Lexington, USA, Email:

Author info »

Description

Bone and glucose metabolism are intricately linked and mutually regulated. Emerging evidence suggests that bone mineralization plays an important role in glucose metabolism, and conversely, glucose homeostasis has been shown to influence Bone Mineral Density (BMD) and fracture risk. This article aims to review the current state of knowledge on the relationship between bone mineralization and glucose metabolism, with a focus on the mechanisms that underlie this relationship.

Bone mineralization and glucose metabolism

Bone mineralization is a complex process that involves the deposition of hydroxyapatite crystals in the extracellular matrix of bone. Hydroxyapatite crystals are composed of calcium and phosphate, which are the two main mineral components of bone. The regulation of bone mineralization is a tightly controlled process that involves the interaction of various hormones and signaling molecules, including Parathyroid Hormone (PTH), vitamin D, and Fibroblast Growth Factor 23 (FGF23).

Recent studies have shown that bone mineralization may play an important role in glucose metabolism. For example, low BMD was associated with an increased risk of developing type 2 diabetes in postmenopausal women [1]. Similarly, low BMD was associated with an increased risk of developing insulin resistance and metabolic syndrome in older men [2].

The mechanisms underlying the relationship between bone mineralization and glucose metabolism are not yet fully understood, but several hypotheses have been proposed. One hypothesis is that bone-derived hormones, such as osteocalcin and adiponectin, play a role in glucose metabolism. Osteocalcin is a bone-derived hormone that regulates glucose metabolism by stimulating insulin secretion and improving insulin sensitivity. Adiponectin is another hormone that is secreted by adipose tissue and has been shown to improve insulin sensitivity and glucose uptake in skeletal muscle [3]. Recent studies have shown that both osteocalcin and adiponectin are involved in the regulation of glucose metabolism and may play a role in the relationship between bone mineralization and glucose metabolism [4].

Another hypothesis is that calcium and vitamin D, which are essential for bone mineralization, also play a role in glucose metabolism. Calcium is involved in insulin secretion and glucose uptake in skeletal muscle, and vitamin D deficiency has been associated with insulin resistance and type 2 diabetes. Recent studies have shown that calcium and vitamin D supplementation may improve glucose metabolism in individuals with type 2 diabetes [5].

Clinical implications

The relationship between bone mineralization and glucose metabolism has important clinical implications. For example, individuals with low BMD may be at increased risk for developing type 2 diabetes and metabolic syndrome, and may benefit from interventions that improve bone health, such as calcium and vitamin D supplementation, exercise, and weightbearing activities [1]. Similarly, individuals with type 2 diabetes or metabolic syndrome may benefit from interventions that improve bone health, such as osteoporosis medications, to reduce their risk of fracture [2].

Conclusion

In conclusion, bone mineralization and glucose metabolism are two important physiological processes that are closely related. Disturbances in one process can affect the other, and vice versa. Therefore, it is important to maintain optimal bone health and glucose metabolism in order to promote overall health and reduce the risk of chronic diseases such as osteoporosis and type 2 diabetes. Future research is needed to better understand the mechanisms underlying the connection between these two processes and to develop new treatments that can improve both bone health and glucose metabolism.

References

1. Shanbhogue VV, Mitchell DM, Rosen CJ, Bouxsein ML. Type 2 diabetes and the skeleton: New insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4(2):159-173.

   [Crossref] [Google Scholar] [PubMed]

2. Srikanthan P, Crandall CJ, Miller‐Martinez D, Seeman TE, Greendale GA, Binkley N, et al. Insulin resistance and bone strength: Findings from the study of midlife in the United States. J Bone Miner Res. 2014;29(4):796-803.

   [Crossref] [Google Scholar] [PubMed]

3. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.

   [Crossref] [Google Scholar] [PubMed]

4. Karsenty G, Olson EN. Bone and muscle endocrine functions: Unexpected paradigms of inter-organ communication. Cell. 2016;164(6):1248-1256.

   [Crossref] [Google Scholar] [PubMed]

5. Neyestani TR, Nikooyeh B, Kalayi A, Zahedirad M, Shariatzadeh N. A vitamin D-calcium-fortified yogurt drink decreased serum PTH but did not affect osteocalcin in subjects with type 2 diabetes. Int J Vitam Nutr Res. 2015;85(1):61-69.

   [Crossref] [Google Scholar] [PubMed]